Ledipasvir (acetone)
≥99%
- Product Code: 101201
CAS:
1441674-54-9
| Molecular Weight: | 947.08 g./mol | Molecular Formula: | C₅₂H₆₀F₂N₈O₇ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Ledipasvir (acetone) is primarily used in the pharmaceutical industry as a key intermediate in the synthesis of Ledipasvir, an antiviral medication. Ledipasvir is a crucial component of combination therapies for treating chronic hepatitis C virus (HCV) infections, particularly genotypes 1, 4, 5, and 6. It works by inhibiting the HCV NS5A protein, which is essential for viral replication. The acetone derivative plays a role in the purification and crystallization processes during the manufacturing of Ledipasvir, ensuring high purity and efficacy of the final drug product. This compound contributes to the development of effective treatments that improve patient outcomes, reduce viral load, and achieve sustained virologic response in HCV-infected individuals.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Powder |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.002 | 10-20 days | €213.69 |
+
-
|
| 0.005 | 10-20 days | €327.14 |
+
-
|
| 0.025 | 10-20 days | €923.37 |
+
-
|
| 0.100 | 10-20 days | €2,637.94 |
+
-
|
Ledipasvir (acetone)
Ledipasvir (acetone) is primarily used in the pharmaceutical industry as a key intermediate in the synthesis of Ledipasvir, an antiviral medication. Ledipasvir is a crucial component of combination therapies for treating chronic hepatitis C virus (HCV) infections, particularly genotypes 1, 4, 5, and 6. It works by inhibiting the HCV NS5A protein, which is essential for viral replication. The acetone derivative plays a role in the purification and crystallization processes during the manufacturing of Ledipasvir, ensuring high purity and efficacy of the final drug product. This compound contributes to the development of effective treatments that improve patient outcomes, reduce viral load, and achieve sustained virologic response in HCV-infected individuals.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :